Barinthus Biotherapeutics (BRNS) announced an update on its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. In the single ascending dose, SAD, portion of the trial, VTP-1000 was well tolerated with no treatment-related serious adverse events, SAEs, and a dose-dependent pharmacological effect observed. The multiple ascending dose, MAD, portion of the trial, which includes a gluten challenge, is ongoing with data expected in the second half of 2026. The SAD portion of the Phase 1 AVALON trial enrolled 18 patients in three placebo-controlled cohorts of ascending doses. VTP-1000 was well tolerated at all dose levels with no treatment-related SAEs. Pharmacological data collected showed a dose-dependent effect.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Buy Rating for Barinthus Biotherapeutics: Promising Clinical Developments and Strategic Merger with Clywedog Therapeutics
- Barinthus Biotherapeutics price target raised to $4 from $3 at H.C. Wainwright
- Barinthus Biotherapeutics Reports Q3 2025 Earnings
- Barinthus Biotherapeutics reports Q3 EPS (36c) vs (21c) last year
- Barinthus Biotherapeutics Advances Celiac Disease Treatment with VTP-1000 Trial